Baird Financial Group Inc. decreased its position in shares of Juno Therapeutics Inc (NASDAQ:JUNO) by 22.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,677 shares of the biopharmaceutical company’s stock after selling 1,650 shares during the quarter. Baird Financial Group Inc.’s holdings in Juno Therapeutics were worth $259,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of JUNO. DekaBank Deutsche Girozentrale increased its position in shares of Juno Therapeutics by 27.9% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 61,900 shares of the biopharmaceutical company’s stock valued at $1,712,000 after buying an additional 13,500 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new position in Juno Therapeutics during the 3rd quarter worth about $5,428,000. Sivik Global Healthcare LLC bought a new position in Juno Therapeutics during the 3rd quarter worth about $2,467,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Juno Therapeutics by 368.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,792 shares of the biopharmaceutical company’s stock worth $708,000 after purchasing an additional 12,421 shares in the last quarter. Finally, Capital Guardian Trust Co. bought a new position in Juno Therapeutics during the 3rd quarter worth about $37,400,000. 70.19% of the stock is currently owned by hedge funds and other institutional investors.
In related news, EVP Robert Azelby sold 1,816 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $44.96, for a total value of $81,647.36. Following the transaction, the executive vice president now owns 70,832 shares in the company, valued at $3,184,606.72. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Hans Edgar Bishop sold 270,250 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $46.17, for a total transaction of $12,477,442.50. Following the completion of the transaction, the chief executive officer now owns 2,772,679 shares in the company, valued at approximately $128,014,589.43. The disclosure for this sale can be found here. In the last quarter, insiders have sold 473,031 shares of company stock worth $27,031,205. 15.08% of the stock is owned by company insiders.
Shares of Juno Therapeutics Inc (NASDAQ:JUNO) traded up $0.09 during trading on Friday, reaching $86.96. 3,696,100 shares of the company’s stock were exchanged, compared to its average volume of 5,484,542. The firm has a market capitalization of $9,930.00, a price-to-earnings ratio of -16.16 and a beta of 3.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.61 and a quick ratio of 4.77. Juno Therapeutics Inc has a 1 year low of $19.62 and a 1 year high of $87.01.
A number of equities analysts have recently commented on the stock. Standpoint Research restated a “hold” rating on shares of Juno Therapeutics in a research note on Wednesday, January 24th. JPMorgan Chase & Co. restated a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, January 11th. Wells Fargo & Co reiterated a “market perform” rating and issued a $63.00 target price (up from $54.00) on shares of Juno Therapeutics in a research note on Wednesday, January 17th. Barclays downgraded shares of Juno Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $55.00 to $87.00 in a research note on Wednesday, January 24th. Finally, Leerink Swann cut shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating and increased their price target for the company from $56.00 to $87.00 in a report on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, eighteen have issued a hold rating and two have assigned a buy rating to the stock. Juno Therapeutics presently has a consensus rating of “Hold” and an average price target of $52.55.
COPYRIGHT VIOLATION NOTICE: “Baird Financial Group Inc. Has $259,000 Position in Juno Therapeutics Inc (JUNO)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/16/baird-financial-group-inc-cuts-stake-in-juno-therapeutics-inc-juno.html.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.